

Regioselective Synthesis of Heterocycles Containing Nitrogen Neighboring an Aromatic Ring by Reductive Ring Expansion Using Diisobutylaluminum Hydride and Studies on the Reaction Mechanism

Hidetsura Cho,^{*,†,‡} Yusuke Iwama,[‡] Kenji Sugimoto,[‡] Seiji Mori,[§] and Hidetoshi Tokuyama^{*,‡}

[†]Graduate School of Science, and [‡]Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan, and [§]Faculty of Science, Ibaraki University, 2-1-1 Bunkyo, Mito, Ibaraki, 310-8512, Japan

hcho@mail.pharm.tohoku.ac.jp; tokuyama@mail.pharm.tohoku.ac.jp

Received October 9, 2009



A systematic investigation of the reductive ring-expansion reaction of cyclic ketoximes fused to aromatic rings with diisobutylaluminum hydride (DIBALH) is described. This reaction regioselectively afforded a variety of five- to eight-membered bicyclic heterocycles or tricyclic heterocycles containing nitrogen neighboring an aromatic ring, including indoline, 1,2,3,4,5,6-hexahydrobenz[b]azocine, 3,4-dihydro-2*H*-benzo[b][1,4]oxazine, 2,3,4,5-tetrahydrobenz[b][1,4]thiazepine, 1,2,3,4,5,6-hexahydroazepino[3,2-b]-indole, 2,3,4,5-tetrahydro-1*H*-benzothieno[2,3-b]azepine, 2,3,4,5-tetrahydro-1*H*-benzothieno[3,2-b]-azepine, 5,6-dihydrophenanthridine, and 5,6,11,12-tetrahydrodibenz[b,f]azocine. The reaction mechanism leading to the rearrangement was investigated on the basis of the restricted Becke three-parameter plus Lee–Yang–Parr (B3LYP) density functional theory (DFT) with the 6-31G (d) basis set. It was found that the reaction proceeds through a three-centered transition state via a stepwise mechanism because the potential energy curve along the intrinsic reaction coordinate (IRC) had two maxima (saddle points; **TS1** and **TS2**) and the partial phenonium cation intermediate **C**. In addition to cyclic ketoximes fused to aromatic rings, the reactions of various cyclic and acyclic ketoximes were examined to investigate preference of migrating group. It was found that the more electron-rich group migrated preferentially to give the corresponding secondary amines.

Introduction

Development of new synthetic methods for the unsubstituted basic skeletons of heterocycles is important from

DOI: 10.1021/jo902177p Published on Web 12/29/2009 © 2009 American Chemical Society the viewpoint of both synthetic and medicinal chemistry. Synthesis of five- to eight-membered bicyclic or tricyclic fused heterocycles containing nitrogen neighboring an aromatic ring, such as hydrogenated benzazepine, benzoxazine,



FIGURE 1. Heterocycles containing nitrogen neighboring an aromatic ring.

SCHEME 1. Regiochemical Problem with Beckmann Rearrangement



benzoxazepine, benzthiazine, or benzthiazepine (Figure 1), is particularly important because these are the core structures of medicines or clinical candidates. In addition, hydrogenated benzazocine, dibenzoazocine, phenanthridine, azepino[3,2-*b*]indole, and so on are also attractive as partial structures for medicines, although these compounds have not been widely used due to lack of synthetic methods.

Despite their importance, the formation of unsubstituted core structures of bicyclic or tricyclic heterocycles containing nitrogen neighboring an aromatic ring has not yet been well investigated because of the difficulty in synthesizing these simple structures. There are only a few straightforward methods available for selective synthesis of these compounds. While Beckmann rearrangement or Schmidt rearrangement of bicyclic aryl ketones would be the method of choice, these methods generally give rise to a mixture of two isomeric lactam derivatives without high selectivity. For example, Beckmann rearrangement of 1 with PPMA^{1,2} or PCl₅³ (Scheme 1) or Schmidt rearrangement of 3 with NaN₃-HCl⁴ (Scheme 2) provides a mixture of two isomeric lactam derivatives 2a and 2b with low selectivity. In order to synthesize compound 2a (or 2c) exclusively, conventional lengthy step-by-step synthesis of ketolactam via Dieckmann condensation with further transformations are required (Scheme 3).⁵

During their investigations into the synthesis of arginine vasopressin (AVP) antagonists (Figure 2), Cho and coworkers developed a straightforward method for the synthesis of bicyclic heterocycles containing nitrogen neighboring an aromatic ring by reductive ring-expansion reaction of

(5) Kunick, C. Arch. Pharm. (Weinheim) 1991, 324, 579-581.

SCHEME 2. Regiochemical Problem with Schmidt Rearrange-



SCHEME 3. Step-by-Step Synthesis of a Lactam Derivative



oximes with DIBALH^{2,6} (Scheme 4). Significantly, the desired bicyclic heterocycle containing nitrogen neighboring an aromatic ring could be obtained exclusively from either *syn* or *anti* oximes, suggesting that the reaction mechanisms were different from Beckmann rearrangement. This method has made it feasible to perform the regioselective synthesis of a series of unsubstituted basic skeletons of heterocycles, such as 5,6,7,8-tetrahydro-4*H*-thieno[3,2-*b*]-azepine, 5,6,7,8-tetrahydro-4*H*-furo[3,2-*b*]azepine, and 5,6,7,8-tetrahydro-4*H*-pyrro[3,2-*b*]azepine, as the sole product in good yield.

As a seminal study in this area, Yamamoto and Maruoka reported on the reductive rearrangement of oximes with DIBALH providing the corresponding secondary amines.⁷ They also reported several examples of exclusive generation of secondary amines from unsymmetrical ketoximes, although the detailed reaction mechanisms were not described. After Cho's preliminary report,^{2a} Torisawa⁸ and Willand⁹ more recently applied the ring-expansion reaction with DIBALH to synthesis

⁽¹⁾ Danaruma, L. G.; Heldt, W. E. Org. React. 1960, 11, 1-156.

^{(2) (}a) Cho, H.; Murakami, K.; Nakanishi, H.; Isoshima, H.; Hayakawa, K.; Uchida, I. *Heterocycles* **1998**, *48*, 919–927. (b) Cho, H.; Matsuki, S. *Heterocycles* **1996**, *43*, 127–131.

⁽³⁾ Aparajithan, K.; Thompson, A. C.; Sam, J. J. Heterocycl. Chem. 1966, 3, 466–469.

⁽⁴⁾ Wolff, H. Org. React. 1946, 307-336.

^{(6) (}a) Cho, H.; Murakami, K.; Nakanishi, H.; Fujisawa, A.; Isoshima, H.; Niwa, M.; Hayakawa, K.; Hase, Y.; Uchida, I.; Watanabe, H.; Wakitani, K.; Aisaka, K. J. Med. Chem. 2004, 47, 101–109. (b) Cho, H.; Wakitani, K. Japan Patent Application, H7-291540 (Nov 9, 1995), WO97/17349. (c) Cho, H.; Murakami, K.; Fujisawa, A.; Niwa, M.; Nakanishi, H.; Uchida, I. Heterocycles 1998, 48, 1555–1566.

^{(7) (}a) Hattori, K.; Matsumura, Y; Miyazaki, T.; Maruoka, K.; Yamamoto, H. J. Am. Chem. Soc. **1981**, 103, 7368–7370. (b) Sasatani, S.; Miyazaki, T.; Maruoka, K.; Yamamoto, H. Tetrahedron Lett. **1983**, 24, 4711–4712. (c) Fujiwara, J.; Sano, H.; Maruoka, K.; Yamamoto, H. Tetrahedron Lett. **1984**, 25, 2367–2370.

⁽⁸⁾ Torisawa, Y.; Nishi, T.; Minamikawa, J. Bioorg. Med. Chem. Lett. 2002, 12, 387–390.

 ⁽⁹⁾ Willand, N.; Beghyn, T.; Nowogrocki, G.; Gesquiere, J.-C.; Deprez,
 B. *Tetrahedron Lett.* 2004, 45, 1051–1054.



FIGURE 2. Structures of an arginine vasopressin (AVP) antagonist and a human urate transporter-1 (URAT-1) inhibitor.

SCHEME 4. Preliminary Studies for the Reductive Ring-Expansion Reaction of Oximes with DIBALH



of heterocyclic compounds. On the other hand, Ortiz-Marciales¹⁰ reported the synthesis of similar heterocycles by rearrangement of *O*-silylated oximes via reduction with borane in the presence of boron trifluoride. In addition, Naito and Miyata described treatment of oxime ethers with alkyl metal species, such as Grignard reagents or alkyllithium, to achieve alkylative ring expansion.¹¹

Although several analogous reactions have been reported, both the general applicability¹² and the detailed reaction mechanisms have not yet been studied. In particular, there remains some confusion about the mechanisms of reductive rearrangement reactions compared with that of Beckmann rearrangement. In this paper, we describe the scope and limitation of reductive rearrangement of oximes with DIBALH, including application to synthesis of five- to eight-membered bicyclic or tricyclic heterocycles. The results of detailed mechanistic studies based on density functional theory (DFT) are also reported.

Results and Discussion

1. Scope and Limitations of Reductive Rearrangement of Oximes with DIBALH. A series of oximes $5a-z^{13}$ were

prepared in pyridine from 2–4 equiv of hydroxylamine hydrochloride and the corresponding aryl ketones, which are commercially available or reported in the literature,¹⁴ and were subjected to reductive rearrangement (Tables 1, 2, and 4–6). The general procedure involved reaction of an *E*, *Z* mixture of oximes with 6 equiv of a hexane solution of DIBALH at 0 °C to room temperature, after which the reaction mixture was treated with NaF to obtain the corresponding linear, bicyclic, or tricyclic secondary amines in good to excellent yields.

1.1. Reaction of Carbocyclic or Heterocyclic Ketoximes Fused to a Benzene Ring. The reductive rearrangement reaction was widely applicable, and oximes derived from four- to seven-membered cyclic ketones could be used to provide the corresponding ring expanded cyclic secondary amines in good to excellent yields (Table 1). For instance, reaction of carbocyclic ketoximes 5a, 5b, 5c, or 5d resulted in indoline 6a, 1,2,3,4tetrahydroquinoline **6b**, 2,3,4,5-tetrahydro-1*H*-benz[*b*]azepine **6c**,¹⁰ and 1,2,3,4,5,6-hexahydrobenz[b]azocine **6d**,¹⁵ respectively (entries 1-4). Interestingly, the relatively strained benzocyclobutenone oxime smoothly underwent reductive rearrangement to give indoline with a small amount (4%) of an indole byproduct. In addition, a variety of heterocyclic ketoximes with five- or six-membered oxygen- or sulfurcontaining rings served as good substrates for the reaction. Thus, coumaran-3-one oxime 5e, chroman-4-one oxime 5f, thioindoxyl oxime 5g, and thiochroman-4-one oxime 5h were converted to 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine $6e^{16}$ 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine **6f**,¹⁰ 3,4-dihydro-2*H*-benzo[*b*][1,4]thiazene **6g**,¹⁷ and 2,3,4,5-tetrahydrobenzo-[*b*][1,4]thiazene **6h**,¹⁷ respectively (entries 5–8). These compounds should be valuable in the field of medicinal chemistry. In particular, 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine **6e** is important as a precursor of a human URAT-1 (urate transporter-1) inhibitor, 2,6-dichloro-4-(2,3-dihydro-1,4-benzoxazin-4-ylcarbonyl)phenol (Figure 2), which was synthesized in one step by acylation of 6e with 3,5-dichloro-4-hydroxybenzoyl chloride.18

1.2. Reductive Ring-Expansion Reaction of Tricyclic Heteroaryl Ketoximes. Next, we examined the reductive ring-expansion reaction of tricyclic ring systems (Table 2).

⁽¹⁰⁾ Ortiz-Marciales, M.; Rivera, L. D.; Jesús, M. D.; Espinosa, S.; Benjamin, J. A.; Casanova, O. E.; Figueroa, I. G.; Rodríguez, S.; Correa, W. J. Org. Chem. 2005, 70, 10132–10134.

⁽¹¹⁾ Mukhopadhyay, P. P.; Miyata, O.; Naito, T. Synlett 2007, 1403-1406.

⁽¹²⁾ Cho, H.; Iwama, Y.; Sugimoto, K.; Kwon, E.; Tokuyama, H. *Heterocycles* **2009**, *78*, 1183–1190.

⁽¹³⁾ The spectral data of oximes 5a, 5b, 5c, 5d, 5e, 5f, and 5m are identical with those reported previously. (a) For 5a, see: Bubb, W. A.; Sternhell, S. Aust. J. Chem. 1976, 29, 1685–1697. (b) For 5b and 5c, see: Zhao, H.; Vandenbossche, C. P.; Koenig, S. G.; Singh, S. P.; Bakale, R. P. Org. Lett. 2008, 10, 505–507. (c) For 5d, see: Bonvallet, P. A.; Todd, E. M.; Kim, Y. S.; McMahon, R. J. J. Org. Chem. 2002, 67, 9031–9042. (d) For 5e and 5f, see: Clive, D. L. J.; Pham, M. P.; Subedi, R. J. Am. Chem. Soc. 2007, 129, 2713–2717. (e) For 5i, see: Bascop, S.-I.; Laronze, J.-Y.; Sapi, J. Monatsh. Chem. 1999, 130, 1159–1166. (f) For 5m, see: Jain, N.; Kumar, A.; Chauhan, S. M. S. Tetrahedron Lett. 2005, 46, 2599–2602.

⁽¹⁴⁾ The precursor ketones of **5b**, **5c**, **5d**, **5f**, **5h**, **5k**, and **5n** are commercially available. Precursor ketones of **5a**, **5e**, **5g**, and **5i** were prepared according to procedures in the literature. (a) For the precursor ketone of **5a**, see: Bubb, W. A.; Sternhell, S. *Aust. J. Chem.* **1976**, *29*, 1685–1697. (b) For the precursor ketone of **5e**, see: Inoue, A.; Kitagawa, K.; Shinokubo, H.; Oshima, K. *J. Org. Chem.* **2001**, *66*, 4333–4339. (c) For the precursor ketone of **5g**, see: Mukherjee, C.; Kamila, S.; De, A. *Tetrahedron* **2003**, *59*, 4767– 4774. (d) For the precursor ketone of **5i**, see: Li, X; Vince, R. *Bioorg. Med. Chem.* **2006**, *14*, 2942–2955. (e) For cyclization from the carboxylic acid to the precursor ketone of **5j**, see: Cho, H.; Matsuki, S. *Heterocycles* **1996**, *43*, 127–131. Maertens, F.; Toppet, S.; Hoornaert, G. J.; Compernolle, F. *Tetrahedron* **2005**, *61*, 1715–1722. (f) For new synthesis of the precursor ketone of **5k**, see Scheme S1 shown in the Supporting Information. (As for the starting material, 2-iodobenzo[*b*]thiophene, consult ref S1 in the Supporting Information.) (g) For the precursor ketone of **51**, see: Horaguchi, T.; Kubo, T.; Tanemura, K.; Suzuki, T. *J. Heterocyclic. Chem.* **1998**, *35*, 649–653.

⁽¹⁵⁾ Ahlbrecht, H.; Düber, E. O.; Epsztajn, J.; Marcinkowski, R. M. K. Tetrahedron 1984, 40, 1157–1165.

⁽¹⁶⁾ Torraca, K. E.; Kawabe, S.-I.; Buchwald, S. L. J. Am. Chem. Soc. 2000, 122, 12907–12908.

⁽¹⁷⁾ Mukheerjee, C.; Biehl, E. Heterocycles 2004, 63, 2309-2318.

⁽¹⁸⁾ Hirata, K.; Ogawa, N.; Sinagawa, Y.; Kiguchi, T.; Inoue, T.; Komeda, Y.; Yamashita, I.; Kamiya, Y. Application WO 2007139002, WO 2007-JP60678, Priority: JP 2006-147261, US 2006-809966. Hirata et. al. synthesized the human URAT-1 inhibitor in several steps by using compound 6e obtained from the reaction of 2*H*-1,4-benzoxazin-3(4*H*)-one with sodium bis(2-methoxyethoxy)aluminum hydride in toluene at rt.

 TABLE 1.
 Reductive Ring-Expansion Reaction of Carbocyclic or Heterocyclic Ketoximes Fused to a Benzene Ring



^{*a*}Ketone (1 equiv) and hydroxylamine hydrochloride (2 equiv) were used in pyridine at rt for 1–6 h. ^{*b*}Oxime (1 equiv) and DIBALH (6 equiv) were used in CH₂Cl₂ at rt for 2–2.5 h. ^{*c*}Ketone (1 equiv) and hydroxylamine hydrochloride (4 equiv) were used in pyridine for 4 h.

We found that the reaction was also applicable to cyclic ketoximes fused to indole and benzothiophene. Reaction of oxime 5i,14 prepared from 1,2,3,4-tetrahydrocarbazol-4one,¹³ proceeded as expected to furnish 1,2,3,4,5,6-hexahydroazepino[3,2-b]indole 6i as the sole product. Due to its instability, the yield of 6i was determined after transformation 6-(4-nitrobenzoyl)-1,2,3,4,5,6-hexahydroazepino[3,2-b]to indole 7i by benzoylation with p-nitrobenzoyl chloride and Et_3N in CH_2Cl_2 (entry 1). The structure of 7i was unambiguously determined by X-ray crystallographic analysis, as reported previously.¹² In contrast, reaction of oxime **5**j derived from 2,3,4,9-tetrahydrocarbazol-1-one gave a complex mixture under the same reaction conditions and the desired tricyclic compound 6j was not detected. On the other hand, benzothiophene derivatives behaved in different manner. Thus, reaction of 51 furnished 2,3,4,5-tetrahydro-1Hbenzothieno[2,3-b]azepine 6l in 73% yield, while oxime 5k





Ketone (1 equiv) and hydroxylamine hydrochloride (2 equiv) were used in pyridine at rt for 2–6 h. ^bOxime (1 equiv) and DIBALH (6 equiv) were used in CH₂Cl₂ at 0 °C to rt for 2–4 h. ^cOxime (1 equiv) and DIBALH (9 equiv) were used in CH₂Cl₂/THF (2:1) at 0 °C to rt for 1 h. ^dThe yield was based on the oximes. ^cKetone (1 equiv) and hydroxylamine hydrochloride (6 equiv) were used in pyridine at rt for 3.5 h. ^fOxime (1 equiv) and DIBALH (7 equiv) were used in CH₂Cl₂ at –10 °C for 3 h. ^gKetone (1 equiv) and hydroxylamine hydrochloride (4 equiv) were used in pyridine at 115 °C for 11 h.

SCHEME 5. Same Product obtained from Isolated (*E*)- and (*Z*)-Oxime



derived from the corresponding ketone^{14f} gave 2,3,4,5-tetrahydro-1*H*-benzothieno[3,2-*b*]azepine **6k** in only a modest yield. Compound **6k** was determined after conversion to **7k**, and was found to be a mixture (6.6:1.0) of rotamers according to ¹H NMR and ¹³C NMR spectra.





The reaction was also tested using tricyclic ketoximes derived from cyclic diaryl ketone derivatives. For example, 9-fluorenone oxime **5m** underwent rearrangement to give 5,6-dihydrophenanthridine **6m**¹⁹ in good yield. The ring-expansion reaction of the seven-membered ring cyclic ketoxime **5n** prepared from the corresponding ketone under relatively strong conditions (refluxed in pyridine for 11 h) required a longer reaction time (3–4 h) but afforded 5,6,11,12-tetrahydrodibenz[*b*,*f*]azocine **6n** in 73% yield.

2. Theoretical Studies on the Mechanisms of Reductive ringexpansion Reactions. As mentioned in the Introduction, the mechanism of the reductive ring-expansion reaction of oximes with DIBALH has not vet been well investigated. although it has been suggested to be similar to Beckmanntype rearrangement. In a previous report,^{2a} we proposed a mechanism that was different from Beckmann-type rearrangement^{7a} based on several experimental findings. For example, both (E)- and (Z)-oximes derived from 4,5,6,7tetrahydro-4-oxobenzo[b]furan were separated, and treatment of each oxime with excess DIBALH gave the same product, 5,6,7,8-tetrahydrofuro[3,2-b]azepine (Scheme 5).^{2a} In addition, the same reaction using a mixture of (E)- and (Z)-oximes derived from 4,5,6,7-tetrahydro-4-oxobenzo-[b]thiophen gave 5,6,7,8-tetrahydrothieno[3,2-b]azepine as a single isomer (Scheme 4), while Beckmann rearrangement gave a mixture of isomeric lactams (Scheme 1). Since the structure of the reductive ring-expansion product was independent of the geometry of the oximes, we considered that the initial step was probably DIBALH reduction of the C-N double bond, followed by rearrangement involving N-O bond cleavage assisted by the aromatic ring to furnish the ring-expansion product with nitrogen attached to the aromatic ring.^{2a} While the initial step of the reaction is reasonable, the detailed mechanism of the rearrangement process

SCHEME 7. Rearrangement from Hydroxylamine Derivative 8 to 2,3,4,5-Tetrahydro-1*H*-benz[*b*]azepine 6c



remains unclear. Against this background, we carried out an extensive investigation into the mechanism of the reductive ringexpansion reaction based on theoretical calculations and eventually proved that the reaction proceeds by reduction of the C-N double bond and subsequent rearrangement by a stepwise mechanism through a three-centered transition state (Scheme 6).

2.1. Confirmation of Intermediacy of Hydroxylamine Derivative. Before starting the theoretical studies, we confirmed that hydroxylamine acts as an intermediate in the reductive ring-expansion reaction. Oxime **5c** was chosen as the test substrate. The corresponding hydroxylamine **8**, prepared by reduction of oxime **5c** with NaBH₃CN, was treated with excess DIBALH (Scheme 7). As expected 2,3,4,5-tetra-hydro-1*H*-benz[*b*]azepine **6c** was isolated in 72% yield as the sole product, indicating that the reaction proceeds via initial formation of aluminum complex (**I**)-*E* and *Z*, followed by 1,2-reduction of the C–N double bond to generate intermediate **II** coordinated by two molecules of dialkyl aluminum (R = *i*-Bu). Finally, reductive rearrangement takes place to furnish the cyclic secondary amine aluminum amide **VII** (R = *i*-Bu).

2.2. Theoretical Studies on the Reaction Mechanisms. Subsequently, the reaction processes from **II** to **6c** was investigated by the aid of 3-parameter hybrid Becke exchange/ Lee-Yang-Parr correlation functional (B3LYP) method.²⁰

⁽¹⁹⁾ Barluenga, J.; Fañanás, F. J.; Sanz, R.; Fernández, Y. Chem.—Eur. J. 2002, 8, 2034–2046.

⁽²⁰⁾ Hehre, W. J.; Radom, L.; Schleyer, P. V. R.; Pople, J. A. *Ab Initio Molecular Orbital Theory*; John Wiley: New York, 1986. References cited therein.

For simplicity, $(i-Bu)_2AlH$ was modeled as Me₂AlH. Two Me₂AlH molecules were added to assess the mechanism, because at least two equivalents of the molecule are necessary for completion of the reaction (one for formation of an aluminum oxide II from (I)-*E* or (I)-*Z*, and the other for reduction of a C=N bond of VI).

The 3D structures of representative intermediates and a saddle point (TS1) (III) with twist-chair conformation on the potential energy surface and the potential energy profile are shown in Figures 3 and 4, respectively. Reduction of E/Zoxime I by dialkylaluminum hydride led to two possible conformers II, which were two aluminum-bound hydroxylamine residues (one with pseudoequatorial substitution and the other with pseudoaxial substitution). The pseudoequatorially substituted hydroxylamine A with twist-chair conformation of II(R = Me) has a slightly lower energy than the pseudoaxially substituted hydroxylamine **B** of **II**, with the difference being 0.1 kJ/mol. Since the π -orbital symmetry of C1 in A does not allow further rearrangement of aromatic carbon into nitrogen, **B** is a direct precursor of the rearrangement. The transition state (TS1) III of the ring opening has an energy level 64.2 kJ/mol higher than the conformer A and 64.1 kJ/mol higher than the conformer **B** based on data shown in Figures 3 and 4 (see the Experimental Section and Supporting Information). We performed intrinsic reaction coordinate (IRC) analysis descending from TS1 toward two-aluminum-bound hydroxylamine derivative **B** and aluminum-coordinated intermediate C (IV). Calculations following the IRC path toward C terminated at a nonstationary point I1 because the potential surfaces around I1 were too flat. Subsequent geometric optimization from I1 is connected to C. The other IRC path from TS1 is connected toward B smoothly. When the benzene C1 atom moves closer to a nitrogen atom, N-O bond cleavage occurs. During the stage between **B** to **TS1**, electrons from a benzene ring, C2, and N flow into the O atom (Table 3). The dipole moments at B and TS1 of 2.3 and 8.8 D, respectively, show that TS1 is more polar than **B**. Then, we employed calculations of solvent polarity effects of CH₂Cl₂ using polarized continuum model $(PCM)^{21}$ at the B3LYP/6-31+G(d) level. We found that the activation energy of 64.1 kJ/mol decreases to 35.6 kJ/mol. At I1, the C1-N distance of 1.60 Å is closer to the C2-N bond length of 1.37 Å, indicating that the C1-C2-N moiety of I1 more closely resembles an aziridine-like structure than TS1. During the stage between TS1 and I1, the C1-C2 bond is only cleaved partially (1.57 Å in the TS1 and 1.64 Å in II) and C1-N bond formation (1.83 Å in the TS1 and 1.60 Å in I1) is more advanced. Additional electron flow from the benzene ring and C2 into N and O then occurs to produce an electrondeficient imine carbon (Table 3). During ring expansion (from III to VI), the N–O bond is cleaved along with Al1–O shortening and N-All bond lengthening (Figure 3 and Scheme 6). In equilibrium structure C (IV) which is higher in energy than B by 38.8 kJ/mol, two aluminum atoms interact with N, and C2 is still interacting with C1. The natural charge of O changes from -0.861 in **B** to -1.327 in **C** (Table 3), and bonds between O and two Al atoms become stronger. Since

(21) Cances, M. T.; Mennucci, B.; Tomasi, J. J. Chem. Phys. 1997, 107, 3032–3041. Cossi, M.; Scalmani, G.; Rega, N.; Barone, V. J. Chem. Phys. 2002, 117, 43–54.



FIGURE 3. Structures of representative intermediates (**B**, **C**, and **D**), TSs (**TS1** and **TS2**), and representative nonstationary point (**I1**) along the IRC. Bond lengths are in angstroms. Total electronic energies (E) at the B3LYP/6-31G(d) level are shown in a.u. The *s* value refers to the reaction coordinate in amu^{1/2} bohr.

the additional positive charge is developed in the benzene ring (+0.400), the intermediate C possesses a partial phenonium cation structure. The decrease of the natural charge of C2 from TS1 (+0.003) to C (+0.202) indicates that C2 changes to an imine carbon character. Once C1–C2 bond cleavage occurs with concomitant Al2–N dissociation through the



FIGURE 4. Potential energy diagram of ring expansion. Relative energies (kJ/mol) are shown in parentheses (B3LYP/6-31G(d)).

 TABLE 3.
 Natural Charges of Stationary Points (B, TS1, C, TS2, D)

 and Representative Nonstationary Points (I1) along the IRC at the B3LYP/

 6-31G(d) Level

	C1	C2	Ν	All	0	C_6H_4
В	-0.048	-0.070	-0.707	+1.860	-0.861	-0.008
TS1	+0.006	+0.003	-0.701	+1.856	-1.188	+0.300
I1	+0.030	+0.107	-0.762	+1.855	-1.293	+0.389
С	+0.074	+0.202	-0.820	+1.852	-1.327	+0.400
TS2	+0.080	+0.213	-0.792	+1.845	-1.332	+0.368
D	+0.130	+0.194	-0.567	+1.850	-1.350	+0.172

second transition state (**TS2**), ring expansion takes place smoothly to furnish **D** (**VI**). The activation energy of the step from **C** to **TS2** is only 1.2 kJ/mol. The exothermic energy of the nitrogen shift to produce **D** (**VI**) relative to **A** is 204.3 kJ/ mol (Figure 4). Thus, we cannot find aziridine as a local minimum (point **I1** along the IRC *s* of +1.82 amu^{1/2} bohr), but can indicate that the reaction proceeds through a threecentered transition state with the stepwise mechanism, because the potential energy curve along the reaction coordinate from **B** to **D** has two maxima (saddle points; **TS1** and **TS2**). Subsequently, reduction of a C=N bond of **VI** with the third molecule of **R**₂AlH affords compound **VII**.

3. Preference of the Migrating Group. As shown in Tables 1 and 2, the reductive rearrangement reaction gave exclusive product due to migration of the aryl group. However, we found that this was not always the case. The oximes **5c** and **5o**²² (Tables 1 and 4) derived from 1-tetralone and 2-methyl-1-tetralone, respectively, provided the expected products 2,3,4,5-tetrahydro-1*H*-benz[*b*]azepine **6c** and 3-methyl-2,3,4,5-tetrahydro-1*H*-benz[*b*]azepine **6o**²³ due to exclusive migration of the aryl groups. However, contrary to our speculation, rearrangement of oxime **5p** prepared from 2,2-dimethyl-1-tetralone gave a mixture of 3,3-dimethyl-1-(4-nitrobenzoyl)-2,3,4,5-tetrahydro-1*H*-benzo

JOC Article

TABLE 4. Products from 2-Substituted Oximes



^{*a*}Ketone (1 equiv) and hydroxylamine hydrochloride (2 equiv) were used in pyridine at rt for 2–6 h. ^{*b*}Oxime (1 equiv) and DIBALH (6 equiv) were used in CH₂Cl₂ at 0 °C to rt for 2 h. ^{*c*}Ketone (1 equiv) and hydroxylamine hydrochloride (4 equiv) were used in pyridine at rt for 6 h. ^{*d*}Ketone (1 equiv) and hydroxylamine hydrochloride (4 equiv) were used in pyridine at 80 °C for 30 h. ^{*c*}The yield was based on the oximes. ^{*f*}The yields of the regioisomers were determined from ¹H NMR spectra of mixtures of the benzoylamides.

 TABLE 5.
 Reductive Rearrangement of Diaryl Ketone Oximes



^{*a*}Ketone (1 equiv) and hydroxylamine hydrochloride (4 equiv) were used in pyridine at rt for 8-12 h. ^{*b*}Oxime (1 equiv) and DIBALH (6 equiv) were used in CH₂Cl₂ at 0 °C to rt for 2 h.

[*b*]azepine **7p** (57%) and 3,3-dimethyl-2-(4-nitrobenzoyl)-2,3,4,5-tetrahydro-1*H*-benzo[*c*]azepine **10p** (22%) after benzoylation of 3,3-dimethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine **6p** and 3,3-dimethyl-2,3,4,5-tetrahydro-1*H*-benzo-[*c*]azepine **9p**, respectively. This result prompted us to investigate the migratory preferences of various substituents.

After choosing unsymmetrical benzophenone oximes bearing different substituents at two para positions each, the influence of electron density on the preference of the migrating group was investigated (Table 5). It was found that the migrating group was clearly dependent on the substituents on the benzene ring and that only the more electron-rich benzene ring underwent migration. Thus, in the case of oxime 5q, exclusive migration of the *p*-anisyl group took place to give

⁽²²⁾ The spectral data of oximes **50**, **5w**, **5x**, **5y**, and **5z** are identical with those reported previously. (a) For **50**, **5x**, and **5y**, see: Zhao, H.; Vandenbossche, C. P.; Koenig, S. G.; Singh, S. P.; Bakale, R. P. *Org. Lett.* **2008**, *10*, 505–507. (b) For **5w**, see: Hwu, J. R.; Tseng, W. N.; Patel, H. V.; Wong, F. F.; Horng, D.-N.; Liaw, B. R.; Lin, L. C. *J. Org. Chem.* **1999**, *64*, 2211–2218. (c) For **5z**, see: Liu, S.; Yu, Y.; Liebeskind, L. S. *Org. Lett.* **2007**, *9*, 1947–1950.

⁽²³⁾ The spectral data of amines **60**, **6v**, **6w**, **6x**, and **6y** are identical with those reported previously. (a) For **60**, see: Ventrice, T.; Campi., E. M.; Roy Jackson, W.; Patti, A. F. *Tetrahedron* **2001**, *57*, 7557–7574. (b) For **6v**, **6w**, **6x**, and **6y**, see: Byun, E.; Hong, B.; De Castro, K. A.; Lim, M.; Rhee, H. *J. Org. Chem.* **2007**, *72*, 9815–9817.

 TABLE 6.
 Preferred Migrating Group During the Reductive Rearrangement of Various Oximes



^{*a*}Ketone (1 equiv) and hydroxylamine hydrochloride (2 equiv) were used in pyridine at rt for 2–6 h. ^{*b*}Oxime (1 equiv) and DIBALH (6 equiv) were used in CH₂Cl₂ at 0 °C to rt for 2 h. ^{*c*}Ketone (1 equiv), hydroxylamine hydrochloride (1.5–2 equiv), and NaOAc (3–5 equiv) were used in MeOH at rt for 1.5 h. ^{*d*}The yield was based on the oximes. ^{*c*}The yields of the regioisomers were determined from ¹H NMR spectra of mixtures of the tosylamides. ^{*f*}Aldehyde (1 equiv), hydroxylamine hydrochloride (2 equiv), and pyridine (5 equiv) were used in MeOH at rt for 30 min. ^{*g*}Ketone (1 equiv), hydroxylamine hydrochloride (1.5 equiv) and NaOAc (3 equiv) were used in EtOH at rt for 6 h. ^{*h*}The yields of the regioisomers were determined from ¹H NMR spectra of mixture of the benzoylamides.

compound $6q^{24}$ in 79% yield. Oxime 5r derived from phenyl *p*-anisyl ketone gave $6r^{25}$ with complete control due to the difference between the methoxy group and hydrogen on the benzene rings. In addition, the CF₃ group controlled migration to furnish $6s^{24}$ as the sole product from the reaction of oxime 5s.

We then prepared a variety of oximes and investigated general trends in the preference of migration. As shown in Table 6, reaction of ethyl methyl ketone oxime **5t** gave a mixture of diethylamine and *N*-methyl-*n*-propylamine, which was determined as (*N*-diethyl)tosylamide **6t**²⁶ and (*N*-methyl-*N*-*n*-propyl)-tosylamide **9t** (3:2) after tosylation. The results indicate that the

primary alkyl group migrates in preference to the methyl group (entry 1). Predominant generation of (N-isopropyl-n-propyl)tosylamide 6u by successive reduction and tosylation of ethyl isopropyl ketone oxime 5u demonstrated that secondary alkyl group is more likely to migrate than the primary alkyl group (entry 2). Reactions using benzaldehyde oxime 5v, acetophenone oxime 5w,²² propiophenone oxime 5x,²² and isopropyl phenyl ketone oxime $5y^{22}$ exclusively gave the corresponding aniline derivatives, *N*-methylaniline 6v,²³ *N*-ethylaniline 6w,²³ *N*-n-propylaniline 6x,²³ and *N*-isobutylaniline 6y,²³respectively, due to migration of the benzene ring, showing that benzene ring migration was preferred over migration of proton, methyl, primary, and secondary alkyl groups. Similar to the rearrangement of oxime 5p shown in Table 4, the exceptional example of generating a mixture of isomeric rearrangement product was 5z,²² which afforded a mixture of 7z (37%) and 10z (31%) after p-nitrobenzoylation of the resulting secondary amines 2,2-dimethylpropylaniline 6z and (N-t-butyl)benzylamine 9z. According to the above data, we concluded that the preference for migration has the following order: phenyl group \approx tertiary alkyl group > secondary alkyl group > primary alkyl group. In addition, an electron-rich phenyl group migrates preferentially in the case of unsymmetrical benzophenone oximes.

Conclusions

We performed a systematic investigation into the reductive ring-expansion reaction of oximes with DIBALH. This method makes it feasible to synthesize a variety of bicyclic or tricyclic heterocycles containing nitrogen attached to an aromatic ring, which are the core structures of medicines or clinical candidates or may have potential as core structure of new drugs. For instance, compound **6e**, obtained by reaction of coumaran-3-one oxime **5e**, is particularly important because it could be converted to 2,6-dichloro-4-(2,3-dihydro-1,4-benzoxazin-4-ylcarbonyl)phenol, which is known to inhibit URAT-1 (urate transporter-1) and could be useful for the treatment of hyperuricemia and gout (Figure 2).¹⁸

Both experimental and theoretical studies were performed to investigate the mechanisms and we obtained some important information. First, it was demonstrated that the reaction proceeds through a hydroxylamine intermediate. Second, DFT calculations revealed that aryl migration occurred by a stepwise mechanism through a three-centered transition state (Figures 3 and 4).

We also clarified the preferences of migrating groups during the reductive rearrangement reaction, and found that the electronic nature of substituents is a crucial factor governing migration preference. For example, the electronrich phenyl group of unsymmetrical benzophenone migrated exclusively and alkyl groups with more substituents migrated more easily, which is similar to the processes observed in Baeyer–Villiger oxidation. We concluded that the order of migration was as follows; phenyl \approx tertiary alkyl group > secondary alkyl group > primary alkyl group.

Finally, considering the practical utility of DIBALH on an industrial scale,²⁷ this reaction may find widespread use not

⁽²⁴⁾ As to determination of the chemical structure of the products, the ¹H NMR data of **6q** and **6s** were respectively identified with those of the compounds synthesized by reductive amination of (*p*-trifluoromethyl)benzaldehyde with *p*-anisidine or aniline, followed by NaBH₄ (Supporting Information, Scheme S2).

⁽²⁵⁾ Sydnes, M. O.; Kuse, M.; Isobe, M. Tetrahedron 2008, 64, 6406-6414.

⁽²⁶⁾ Harmata, M.; Zheng, P.; Huang, C.; Gomes, M. G.; Ying, W.; Ranyanil, K.-O.; Balan, G.; Calkins, N. L. J. Org. Chem. 2007, 72, 683-685.

^{(27) (}a) For an example of using DIBALH in process chemistry, see: Hobson, L. A.; Nugent, W. A.; Anderson, S. R.; Deshmukh, S. S.; Haley, J. J. III; Liu, P.; Magnus, N. A.; Sheeran, P.; Sherbine, J. P.; Stone, B. R. P.; Zhu, J. Org. Process Res. Dev. **2007**, 11, 985–995. (b) In the case of cyclohexanone oxime, large-scale production using DIBALH is also underway at a chemical corporation.

only in the field of medicinal chemistry but also in process chemistry for creation of novel drugs as well as for the synthesis of related natural products.

Experimental Section

General Procedure for the Ring-Expansion Reaction Using DIBALH. Thiochroman-4-one Oxime (5h). To a stirred solution of 1-thiochroman-4-one (4.40 g, 26.8 mmol) in pyridine (50.0 mL) was added hydroxylamine hydrochloride (3.76 g, 54.1 mmol) at rt. After the mixture was stirred for 1.5 h, pyridine was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The aqueous layer was extracted with EtOAc, and the combined organic extracts were washed with brine, dried over MgSO₄, and evaporated under reduced pressure to give the crude material. Purification by column chromatography on a silica gel (EtOAc:n-hexane = 1:3) afforded oxime 5h (4.61 g, 96%): colorless crystals; mp 98-100 °C; IR (KBr) 3233, 2920, 1587, 1475, 1310 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.13 (1H, brs), 7.87 (1H, dd, J = 1.6 and 8.0 Hz), 7.25 (1H, dd, J = 1.6and 8.0 Hz), 7.23 (1H, ddd, J = 1.6, 7.2, and 8.0 Hz), 7.13 (1H, ddd, J = 1.6, 7.2, and 8.0 Hz), 3.19 (2H, t, J = 6.0 Hz), 2.97 (2H, t, J = 6.0 Hz)t, J = 6.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 153.6, 136.3, 129.5, 129.3, 128.4, 125.9, 125.5, 26.2, 25.9; LRMS (EI) m/z 179 (M⁺). Anal. Calcd for C₉H₉NOS: C, 60.31; H, 5.06; N, 7.81. Found: C, 60.40; H, 5.16; N, 7.72.

2,3,4,5-Tetrahydrobenzo[b][1,4]thiazepine Hydrochloride (6h). To a stirred solution of 5h (1.01 g, 5.63 mmol) in CH₂Cl₂ (56.0 mL) was added DIBALH (33.0 mL, 33.7 mmol, 1.02 M in *n*-hexane) over 10 min at 0-5 °C (internal temperature) under an argon atmosphere. Stirring was continued for 5 min at 0 °C and for 2 h at rt. NaF powder (6.76 g, 161 mmol) and water (2.2 mL) were added at 0 °C, and the resulting mixture was stirred for 30 min at the same temperature. Then the reaction mixture was filtered through a Celite pad. The filter cake was washed with EtOAc, and the combined organic solutions were evaporated to give the crude product. Purification by column chromatography on a silica gel ($Et_2O:n$ -hexane = 1:3) yielded 2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine **6h** (662 mg, 71%). The ¹H NMR spectrum was identified with that reported in ref 17. Although 3 mol equiv of DIBALH is theoretically sufficient for this method, we often employed 6-9 mol equiv of the reagent to finish each reaction. To a solution of 6h in Et₂O was added HCl in Et₂O (1 M) at rt. After stirring for 20 min, Et₂O was removed under reduced pressure. The residue was purified by recrystallization (EtOH) to give HCl salts of 6h: colorless crystals; mp 138-142 °C; IR (KBr) 2914, 2687, 1558, 1456, 764 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 7.74 (1H, dd, J = 1.6 and 7.6 Hz), 7.56 (1H, dd, J = 1.6 and 7.6 Hz), 7.51 (1H, ddd, J = 1.6, 7.6, and 7.6 Hz), 7.46 (1H, ddd, J = 1.6, 7.6, and 7.6 Hz), 3.51 (2H, t, J = 5.6 Hz), 2.95 (2H, t, J = 5.6 Hz), 2.40 $(2H, tt, J = 5.6 \text{ and } 5.6 \text{ Hz}); {}^{13}C \text{ NMR} (100 \text{ MHz}, \text{CD}_3\text{OD}) \delta$ 140.9, 136.0, 132.6, 131.3, 131.0, 124.7, 50.9, 32.7, 29.9; LRMS (FAB) m/z 166 (M – Cl). Anal. Calcd for C₉H₁₂ClNS: C, 53.59; H, 6.00; N, 6.94. Found: C, 53.47; H, 5.85; N, 6.89

6-(4-Nitrobenzoyl)-1,2,3,4,5,6-hexahydroazepino[**3,2-***b*]indole (7i). 1,2,3,4,5,6-Hexahydroazepino[**3,2-***b*]indole **6i** was prepared from oxime **5i**, but was unstable. Without purification, benzoylation of **3i** was carried out with *p*-nitrobenzoyl chloride (68.7 mg, 0.370 mmol) and Et₃N (0.100 mL, 0.717 mmol) in CH₂Cl₂ (3.0 mL). Then the reaction mixture was diluted with water and extracted with CH₂Cl₂. The combined organic extracts were washed with brine, dried over anhydrous MgSO₄ and evaporated under reduced pressure. The residue was purified by preparative TLC (EtOAc:*n*-hexane = 1:1) to afford compound **7i** in 63% yield for two steps: colorless crystals; mp 216–217 °C (EtOAc/*n*-hexane); IR (KBr) 3271, 2934, 1632, 1520, 1346, 858, 843 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.02 (1H, s), 7.90 (2H, d, J = 8.8 Hz), 7.55 (2H, d, J = 8.8 Hz), 7.14 (1H, d, J = 8.0 Hz), 6.98 (1H, t, J = 7.6 Hz), 6.92 (1H, d, J = 8.0 Hz), 6.84 (1H, t, J = 7.6 Hz), 5.11 (1H, m), 3.08 (1H, t, J = 13.8 Hz), 2.91 (1H, m), 2.82 (1H, t, J = 12.2 Hz), 2.16–2.03 (3H, m), 1.61 (1H, m); ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 147.8, 143.1, 133.7, 132.9, 128.7, 123.4, 122.7, 121.8, 120.3, 118.7, 116.6, 110.9, 47.6, 31.1, 28.0, 25.3; LRMS (EI) *m/z* 335 (M⁺). Anal. Calcd for C₁₉H₁₇N₃O₃: C, 68.05; H, 5.11; N, 12.53. Found: C, 67.79; H, 5.36; N, 12.45.

1-(4-Nitrobenzoyl)-2,3,4,5-tetrahydro-1*H***-benzothieno[3,2-***b***]-azepine** (**7k**). Compound **7k** (rotamers; 6.6:1.0) was synthesized from 2,3,4,5-tetrahydro-1*H*-benzothieno[3,2-*b*]azepine **6k** in a similar manner: pale yellow crystals; mp 180–183 °C; IR (KBr) 2941, 1647, 1522, 1348, 849 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.26 (0.26H, d, J = 8.8 Hz), 7.90 (1.74H, d, J = 8.8 Hz), 7.68 (0.26H, d, J = 0.8 Hz), 7.58 (0.87H, d, J = 8.4 Hz), 7.48 (1.74H, d, J = 8.8 Hz), 7.38 (0.13H, d, J = 8.4 Hz), 7.16–7.11 (3H, m), 5.10–5.06 (0.87H, m), 3.87–3.84 (0.13H, m), 3.11–3.04 (2H, m), 2.87–2.76 (1H, m), 2.20–2.09 (3H, m); 1.63–1.50 (1H, m); ¹³C NMR (100 MHz, CDCl₃) δ 167.8, 148.1, 142.3, 138.3, 136.0, 135.4, 134.8, 133.9, 128.9, 128.4, 127.4, 125.2, 124.5, 124.45, 124.43, 124.0, 123.8, 122.8, 122.7, 120.0, 48.3, 46.8, 37.1, 31.0, 29.1, 25.7, 23.8, 21.7; LRMS (EI) *m*/*z* 352 (M⁺); HRMS (EI) *m*/*z* calcd for C₁₉H₁₆N₂O₃S 352.0882 (M⁺), found 352.0862.

2,3,4,5-Tetrahydro-1*H***-benzothieno**[**2,3-***b*]**azepine** (**6**]**:** colorless oil; IR (KBr) 3254, 2924, 1645, 1435, 752 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.56 (1H, dd, J = 1.2 and 8.0 Hz), 7.42 (1H, dd, J = 1.2 and 8.0 Hz), 7.27 (1H, ddd, J = 1.2, 8.0, and 8.0 Hz), 7.11 (1H, ddd, J = 1.2, 8.0, and 8.0 Hz), 4.08 (1H, br s), 3.18 (2H, t, J = 5.6 Hz), 2.77 (2H, t, J = 6.0 Hz), 1.89 (2H, tt, J = 5.2 and 5.6 Hz), 1.73 (2H, tt, J = 5.2 and 6.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 149.1, 141.4, 132.6, 124.1, 121.65, 121.61, 119.4, 116.8, 49.1, 32.3, 26.7, 26.5; LRMS (EI) *m*/*z* 203 (M⁺); HRMS (EI) *m*/*z* calcd for C₁₅H₁₃NO 203.0769 (M⁺), found 203.0753.

Dibenzosuberone oxime (**5n**): colorless crystals; mp 167–170 °C; IR (KBr) 3227, 1489, 1445, 1423, 997 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.86 (1H, br s), 7.56 (1H, d, J = 8.0 Hz), 7.45 (1H, d, J = 7.2 Hz), 7.31–7.23 (4H, m), 7.18 (1H, dd, J = 7.2 and 7.6 Hz), 7.11 (1H, d, J = 7.6 Hz), 3.15–3.12 (4H, m); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 138.8, 138.4, 134.4, 133.7, 130.4, 129.3, 129.2, 128.6, 128.3, 126.2, 125.6, 33.6, 32.1; LRMS (EI) *m*/*z* 223 (M⁺); HRMS (EI) *m*/*z* calcd for C₁₅H₁₃NO 223.0997 (M⁺), found 223.0993.

5,6,11,12-Tetrahydrodibenz[*b*,*f*]azocine (6n): colorless crystals; mp 128–130 °C; IR (KBr) 3364, 2924, 1603, 1477 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.10–7.05 (3H, m), 7.02 (1H, dd, *J* = 1.6 and 8.0 Hz), 6.97 (1H, dd, *J* = 1.6 and 7.6 Hz), 6.89 (1H, ddd, *J* = 1.6, 7.6, and 8.0 Hz), 6.68 (1H, ddd, *J* = 1.6, 7.6, and 7.6 Hz), 6.49 (1H, dd, *J* = 1.6 and 8.0 Hz), 4.42 (2H, s), 3.93 (1H, br s), 3.29 (2H, t, *J* = 7.2 Hz), 3.17 (2H, t, *J* = 7.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 147.3, 140.6, 137.3, 131.1, 130.3, 129.5, 129.3, 127.3, 126.8, 126.5, 120.0, 119.0, 51.8, 35.5, 32.5; LRMS (EI) *m*/*z* 209 (M⁺); HRMS (EI) *m*/*z* calcd for C₁₅H₁₅N 209.1204 (M⁺), found 209.1179.

1,2,3,4-Tetrahydro-N-hydroxy-1-naphthalenamine (8). To a stirred solution of tetralone oxime **5c** (161 mg, 1.00 mmol) in MeOH (2.0 mL) was added sodium cyanoborohydride (189 mg, 3.00 mmol) at rt followed by hydrogen chloride in MeOH (1.0 M, 5.0 mL) at 0 °C. After the mixture was stirred for 5 h at rt, the reaction was quenched with saturated aqueous NaH-CO₃. The reaction mixture was extracted with EtOAc, and the combined extracts were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash column chromatograpy on silica gel (EtOAc:*n*-hexane = 1:1) to give hydroxylamine **8** (124 mg, 76%) as a colorless solid: IR (KBr) 3155, 2941, 2882, 760 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.32 (1H, dd, J = 2.0 and 6.4 Hz), 7.25–7.09 (3H, m), 4.09 (1H, dd, J = 4.0 and 4.0 Hz), 2.84–2.68 (2H, m), 2.25–2.20 (1H, m), 1.95–1.89 (1H, m),

JOC Article

1.85–1.75 (2H, m); ¹³C NMR (100 MHz, CDCl₃) δ 138.5, 134.3, 129.6, 129.2, 127.4, 125.8, 59.3, 29.4, 25.8, 18.3; LRMS (EI) *m*/*z* 163 (M⁺); HRMS (EI) *m*/*z* calcd for C₁₀H₁₃NO (M⁺) 163.0997, found 163.1015.

2,2-Dimethyl-1-tetralone oxime (5p) (1.4:1.0 mixture of (*E*)and (*Z*)-isomers): colorless solid; IR (KBr) 3198, 2916, 1456, 949, 770 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.32 (1H, br s), 8.48 (0.42H, d, *J* = 7.6 Hz), 7.80 (0.58H, d, *J* = 7.6 Hz), 7.29–7.14 (3H, m), 2.91 (0.83H, t, *J* = 6.8 Hz), 2.74 (1.17H, t, *J* = 6.0 Hz), 1.84 (0.83H, t, *J* = 6.8 Hz), 1.68 (1.17H, t, *J* = 6.0 Hz), 1.50 (3.50H, s), 1.21 (2.5H, s); ¹³C NMR (100 MHz, CDCl₃) δ 159.3, 158.2, 140.5, 139.4, 132.4, 131.6, 129.4, 128.6, 127.9, 127.3, 126.5, 125.5, 125.3, 40.9, 37.09, 37.05, 36.8, 27.0, 26.5, 26.2, 24.3; LRMS (EI) *m*/*z* 189 (M⁺); HRMS (EI) *m*/*z* calcd for C₁₂H₁₅NO (M⁺) 189.1154, found 189.1159.

3,3-Dimethyl-2-(4-nitrobenzoyl)-2,3,4,5-tetrahydro-1*H***-benzo-**[*b*]azepine (7p): colorless oil; IR (neat) 2918, 1651, 1524, 1313, 862, 750 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (2H, d, J =8.0 Hz), 7.39 (2H, d, J =8.0 Hz), 7.22 (1H, d, J = 7.6 Hz), 7.08 (1H, dd, J = 7.6 and 7.6 Hz), 6.87 (1H, dd, J = 7.6 and 7.6 Hz), 6.54 (1H, d, J = 7.6 Hz), 4.76 (1H, dd, J = 13.2 Hz), 3.19 (1H, dd, J = 13.6 and 14.0 Hz), 2.73 (1H, dd, J = 6.0 and 13.6 Hz), 1.45 (1H, dd, J = 13.6 and 13.6 Hz), 1.22 (3H, s), 1.02 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ 167.8, 147.9, 143.6, 142.4, 139.3, 130.2, 129.0, 128.0, 127.5, 127.1, 122.9, 56.6, 39.9, 35.7, 30.7, 29.4, 23.2; LRMS (EI) *m*/*z* 324 (M⁺); HRMS (EI) *m*/*z* Calcd for C₁₉H₂₀N₂O₃ (M⁺) 324.1474, found 324.1471.

3,3-Dimethyl-2-(4-nitrobenzoyl)-2,3,4,5-tetrahydro-1*H***-benzo-**[*c*]**azepine** (**10p**): pale yellow solid; IR (KBr) 2957, 1651, 1520, 1350, 860, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (2H, dd, *J* = 1.2 and 8.0 Hz), 7.34 (2H, d, *J* = 8.0 Hz), 7.25–7.21 (2H, m), 7.05 (1H, dd, *J* = 7.6 and 7.6 Hz), 6.42 (1H, d, *J* = 7.6 Hz), 4.33 (2H, br s), 3.18 (2H, t, *J* = 5.2 Hz), 2.11 (2H, t, *J* = 5.2 Hz), 1.69 (6H, s); ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 148.5, 144.1, 138.7, 135.8, 130.3, 128.7, 128.3, 127.6, 125.9, 123.2, 59.5, 50.5, 40.8, 29.6, 25.0; LRMS (EI) *m*/*z* 324 (M⁺); HRMS (EI) *m*/*z* calcd for C₁₉H₂₀N₂O₃ (M⁺) 324.1474, found 324.1487.

4-(Methoxyphenyl) 4-(trifluoromethyl)phenyl ketone oxime (5q) (1:1 mixture of (*E*)- and (*Z*)-isomers): colorless solid; IR (KBr) 3256, 1605, 1512, 1325, 1256, 1163, 1130, 837 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (1H, d, *J* = 8.0 Hz), 7.58–7.61 (2H, m), 7.51 (1H, d, *J* = 8.0 Hz), 7.40–7.36 (2H, m), 6.99 (1H, d, *J* = 9.2 Hz), 6.87 (1H, d, *J* = 9.2 Hz), 3.87 (1.5H, s), 3.82 (1.5H, s); ¹³C NMR (100 MHz, CDCl₃) δ 161.0, 160.4, 156.54, 156.50, 140.2, 136.6, 131.24 (q, *J*_{C-F} = 329 Hz), 131.21, 131.0 (q, *J*_{C-F} = 329 Hz), 129.6, 129.1, 128.5, 127.8, 125.3–125.2 (2C, m), 123.9, 114.0, 113.7, 55.32, 55.30; LRMS (EI) *m/z* 295 (M⁺); HRMS (EI) *m/z* calcd for C₁₅H₁₂F₃NO₂ 295.0820 (M⁺), found 295.0822.

N-(4-Trifluoromethyl)benzyl-4-methoxyaniline (6q): yellow solid; IR (KBr) 3406, 1514, 1327, 1236, 1121, 1067, 820 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.57 (2H, d, J = 8.4 Hz), 7.46 (2H, d, J = 8.4 Hz), 6.76 (2H, d, J = 9.2 Hz), 6.55 (2H, d, J = 9.2 Hz), 4.34 (2H, s), 3.89 (1H, br s), 3.72 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ 152.4, 144.0 (d, J_{C-F} = 23 Hz), 141.9, 129.4 (q, J_{C-F} = 329 Hz), 127.5, 125.5 (q, J_{C-F} = 33 Hz), 122.8, 115.0, 114.2, 55.7, 48.7; LRMS (EI) *m*/*z* 281 (M⁺); HRMS (EI) *m*/*z* calcd for C₁₅H₁₄F₃NO 281.1027 (M⁺), found 281.1032.

Phenyl 4-(trifluoromethyl)phenyl ketone oxime (5s) (mixture of (*E*)- and (*Z*)-isomers): colorless solid; IR (KBr) 3252, 2918, 1616, 1456, 1408, 1323, 1113, 1069, 994 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.67 (1H, br s), 7.74–7.32 (9H, m); ¹³C NMR (100 MHz,

CDCl₃) δ 157.0, 156.9, 139.7, 136.3, 135.4, 131.9, 131.0 (q, $J_{C-F} =$ 321 Hz), 131.1 (q, $J_{C-F} =$ 321 Hz), 129.9, 129.7, 129.5, 129.2, 128.6, 128.4, 128.2, 127.7, 125.3 (2C, m), 122.6, 122.5; LRMS (EI) m/z 265 (M⁺); HRMS (EI) m/z calcd for C₁₄H₁₀F₃NO 265.0714 (M⁺), found 265.0707.

N-[4-(Trifluoromethyl)benzyl]aniline (6s): pale yellow oil; IR (neat) 3420, 1605, 1504, 1327, 1163, 1123, 1067 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.56 (2H, d, J = 8.0 Hz), 7.45 (2H, d, J = 8.0 Hz), 7.15 (2H, dd, J = 7.2 and 8.0 Hz), 6.72 (1H, t, J = 7.2 Hz), 6.58 (2H, d, J = 8.0 Hz), 4.38 (2H, s), 4.09 (1H, br s); ¹³C NMR (100 MHz, CDCl₃) δ 147.6, 143.7, 129.3 (q, $J_{C-F} = 322$ Hz), 129.2, 127.3, 125.5 (q, $J_{C-F} = 37$ Hz), 122.8, 117.9, 112.8, 47.8; LRMS (EI) m/z 251 (M⁺); HRMS (EI) m/z calcd for C₁₄H₁₂F₃N 251.0922 (M⁺), found 251.0923.

Computational Details

All calculations in the present study were performed with the Gaussian 03 program²⁸ and by using the restricted Becke threeparameter plus Lee–Yang–Parr (B3LYP) DFT method with the 6-31G(d) basis set.²⁰ Stationary points were optimized without any symmetry assumption unless otherwise noted. By normal coordination analyses, zero and one imaginary frequency were confirmed for all minima and the saddle points, respectively. Then intrinsic reaction coordinate (IRC) analysis was performed from the saddle point.²⁹ Reaction coordinate *s* was based on a transition state as zero [1 hartree (au) = 2625.4997 kJ/mol]. Cartesian coordinates for representative stationary points are provided in Table S1 (Supporting Information).

Acknowledgment. The generous allotment of computational time by the Research Center for Computational Science (RCCS), the National Institutes of Natural Sciences, Japan, is gratefully acknowledged.

Supporting Information Available: Additional experimental, spectral data on compounds 5a, 5g, (E)-5j, (Z)-5j, 5k, 5l, 5r, 6t, 9t, 5u, 6u, 9u, 7z, and 10z, the new synthetic scheme (five steps) for the precursor ketone of 5k from 2-iodobenzo-[b]thiophene, the synthetic scheme of authentic samples for 6qand 6s, and tables of Cartesian coordinates for the representative stationary points. This material is available free of charge via the Internet at http://pubs.acs.org.

(30) Nicolas, Y; Blanchard, P.; Levillain, E.; Allain, M.; Mercier, N.; Roncali, J. Org. Lett. 2004, 6, 273–276.

⁽²⁸⁾ Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; and Pople, J. A. *Gaussian 03, revision D.02*; Gaussian Inc.: Wallingford, CT, 2004.

^{(29) (}a) Fukui, K. Acc. Chem. Res. **1981**, *14*, 363–368. (c) Gonzalez, C.; Schlegel, H. B. J. Chem. Phys. **1989**, *90*, 2154–2161. (b) Gonzalez, C.; Schlegel, H. B. J. Phys. Chem. **1990**, *94*, 5523–5527.